Micronized progesterone, progestins, and menopause hormone therapy

References

• NAMS. 2017. The 2017 hormone therapy position statement of the North American menopause society. 2017. The NAMS 2017 hormone therapy position statement advisory panel. Menopause 24:728–53.
   PubMed Web of Science ®Google Scholar
• Allen, N. E., K. K. Tsilidis, T. J. Key, L. Dossus, R. Kaaks, E. Lund, K. Bakken, and O. Gavrilyuk. 2010. Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European prospective investigation into cancer and nutrition. American Journal of Epidemiology 172:1394–403.
   PubMed Web of Science ®Google Scholar
• Asi, N., K. Mohammed, Q. Haydour, M. R. Gionfriddo, O. L. Vargas, L. J. Prokop, S. S. Faubion, and M. H. Murad. 2016. Progesterone vs. synthetic progestins and the risk of breast cancer: A systematic review and meta-analysis. Systematic Reviews 5:121. doi:10.1186/s13643-016-0294-5.
   PubMed Web of Science ®Google Scholar
• Baber, R. J., N. Panay, and A. Fenton. 2016. The IMS writing group. 2016 IMS recommendations on women’s midlife health and menopause hormone therapy. Climacteric 19:109–50. doi:10.3109/13697137.2015.1129166.
   PubMed Web of Science ®Google Scholar
• Beral, V., D. Bull, and G. Reeves. 2005. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Million Women Study Collaborators Lancet 365:1543–51.
   PubMed Web of Science ®Google Scholar
• Canonico, M., M. Alhenc-Gelas, G. Plu-Bureau, V. Olié, and P. Y. Scarabin. 2010. Activated protein C resistance among postmenopausal women using transdermal estrogens: Importance of progestin. Menopause 17:1122–27. doi:10.1097/gme.0b013e3181e102eb.
   PubMed Web of Science ®Google Scholar
• Canonico, M., L. Carcaillon, G. Plu-Bureau, E. Oger, A. Singh-Manoux, P. Tubert-Bitter, A. Elbaz, and P. Y. Scarabin. 2016. Postmenopausal hormone therapy and risk of stroke: Impact of the route of estrogen administration and type of progestin. Stroke 47:1734–41. doi:10.1161/STROKEAHA.116.013052.
   PubMed Web of Science ®Google Scholar
• Canonico, M., E. Oger, G. Plu-Bureau, J. Conard, G. Meyer, H. Lévesque, H. Lévesque, N. Trillot, M. T. Barrellier, et al. 2007. Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: Impact of the route of estrogen administration and progestins: The ESTHER study. Circulation 115:840–45. doi:10.1161/CIRCULATIONAHA.106.642280.
   PubMed Web of Science ®Google Scholar
• Casanova, G., and P. M. Spritzer. 2012. Effects of micronized progesterone added to non-oral estradiol on lipids and cardiovascular risk factors in early postmenopause: A clinical trial. Lipids in Health and Disease 11 (Oct):133. doi:10.1186/1476-511X-11-133.
   PubMed Web of Science ®Google Scholar
• Caufriez, A., R. Leproult, M. L’Hermite-Balériaux, M. Kerkhofs, and G. Copinschi. 2011. Progesterone prevents sleep disturbances and modulates GH, TSH, and melatonin secretion in postmenopausal women. The Journal of Clinical Endocrinology and Metabolism 96((4)):E614–23. doi: 10.1210/jc.2010-2558. Apr
   PubMed Web of Science ®Google Scholar
• Chlebowski, R. T., J. E. Manson, G. L. Anderson, J. A. Cauley, A. K. Aragaki, M. L. Stefanick, D. S. Lane, K. C. Johnson, et al. 2013. Estrogen plus progestin and breast cancer incidence and mortality in the women’s health initiative observational study. Journal of the National Cancer Institute 105:526–35. doi:10.1093/jnci/djt043.
   PubMed Web of Science ®Google Scholar
• Cobin, R. H., and N. F. Goodman. AACE Reproductive Endocrinology Scientific Committee. American association of clinical endocrinologists and american college of endocrinology position statement on menopause-2017 update. 2017. Endocrine Practice: Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists July;23(7):869–80. 10.4158/EP171828.PS.
   PubMed Web of Science ®Google Scholar
• Cordina-Duverger, E., T. Truong, A. Anger, M. Sanchez, P. Arveux, P. Kerbrat, and P. Guénel. 2013. Risk of breast cancer by type of menopausal hormone therapy: A case-control study among post-menopausal women in France. PLoS One 8:e78016. doi:10.1371/journal.pone.0078016.
   PubMed Web of Science ®Google Scholar
• Espié, M., J. P. Daures, T. Chevallier, P. Mares, M. C. Micheletti, and P. De Reilhac. 2007. Breast cancer incidence and hormone replacement therapy: Results from the mission study, prospective phase. Gynecological Endocrinology : The Official Journal of the International Society of Gynecological Endocrinology 23:391–97. doi:10.1080/09513590701382104.
   PubMed Web of Science ®Google Scholar
• Farr, J. N., S. Khosla, Y. Miyabara, V. M. Miller, and A. E. Kearns. 2013. Effects of estrogen with micronized progesterone on cortical and trabecular bone mass and microstructure in recently postmenopausal women. The Journal of Clinical Endocrinology and Metabolism 98:E249–57. doi:10.1210/jc.2012-3406.
   PubMed Web of Science ®Google Scholar
• Fournier, A., F. Berrino, and F. Clavel-Chapelon. 2008. Unequal risks for breast cancer associated with different hormone replacement therapies: Results from the E3N cohort study. Breast Cancer Research and Treatment 107:103–11. doi:10.1007/s10549-007-9523-x.
   PubMed Web of Science ®Google Scholar
• Fournier, A., L. Dossus, S. Mesrine, A. Vilier, M. C. Boutron-Ruault, F. Clavel-Chapelon, and N. Chabbert-Buffet. 2014. Risks of endometrial cancer associated with different hormone replacement therapies in the E3N cohort, 1992-2008. American Journal of Epidemiology 180:508–17. doi:10.1093/aje/kwu146.
   PubMed Web of Science ®Google Scholar
• Gillet, J. Y., G. Andre, B.Faguer, R.Erny, M.Buvat-Herbaut, M. A.Domin, J. M.Kuhn, B.Hedon, et al. 1994. Induction of amenorrhea during hormone replacement therapy: Optimal micronized progesterone dose. A multicenter study. Maturitas 19:103–15. doi:10.1016/0378-5122(94)90060-4.
   PubMed Web of Science ®Google Scholar
• Gompel, A. 2012. Micronized progesterone and its impact on the endometrium and breast vs. progestins. Climacteric 15 (Suppl. 1):18–25. doi:10.3109/13697137.2012.669584.
   PubMed Web of Science ®Google Scholar
• Gompel, A. 2018. Progesterone, progestins and the endometrium in perimenopause and in menopausal hormone therapy. Climacteric 21 (4):321–25. doi:10.1080/13697137.2018.1446932.
   PubMed Web of Science ®Google Scholar
• Gompel, A., and G. Plu-Bureau. 2012. Progesterone, progestins and the breast in menopause treatment. Climacteric 21 (4):326–32. doi:10.1080/13697137.2018.1476483.
   Web of Science ®Google Scholar
• Gruber, C. J., and J. C. Huber. 2003. Differential effects of progestins on the brain. Maturitas 46 (Suppl. 1):S71–5. doi:10.1016/j.maturitas.2003.09.021.
   PubMed Web of Science ®Google Scholar
• Hapgood, J. P., D. Africander, R. Louw, R. M. Ray, and J. M. Rohwer. 2014. Potency of progestins used in hormonal therapy: Toward understanding differential actions. The Journal of Steroid Biochemistry and Molecular Biology 142:39–47. doi:10.1016/j.jsbmb.2013.08.001.
   PubMed Web of Science ®Google Scholar
• Hipolito Rodrigues, M. A., and A. Gompel. 2018. Progestatifs. EMC –. Gynécologie 0 ( 0):1–17. [Article 85-A-30].
   Google Scholar
• Hodis, H. N., W. J. Mack, V. W. Henderson, D. Shoupe, M. J. Budoff, J. Hwang-Levine, Y. Li, M. Feng, et al. 2016. ELITE Research Group. Effects of early versus late postmenopausal treatment with estradiol. The New England Journal of Medicine 374:1221–31. doi:10.1056/NEJMoa1505241.
   PubMed Web of Science ®Google Scholar
• Honisett, S. Y., B. Pang, L. Stojanovska, K. Sudhir, and P. A. Komesaroff. 2003. Progesterone does not influence vascular function in postmenopausal women. Journal of Hypertension 21:1145–49. doi:10.1097/00004872-200306000-00014.
   PubMed Web of Science ®Google Scholar
• Jondet, M., M. Maroni, H. Yaneva, S. Brin, F. Peltier-Pujol, and C. Pélissier. 2002. Comparative endometrial histology in postmenopausal women with sequential hormone replacement therapy of estradiol and, either chlormadinone acetate or micronized progesterone. Maturitas 41:115–21. doi:10.1016/S0378-5122(01)00260-2.
   PubMed Web of Science ®Google Scholar
• Kagan, R., G. Constantine, A. Kaunitz, G. Gasper, B. Bernick, and S. Mirkin. 2017. TX-001HR improved the medical outcomes study-sleep (MOSSleep) questionnaire in menopausal women with vasomotor symptoms (S-17). Menopause 24:1431.
   Web of Science ®Google Scholar
• King, R. J., and M. I. Whitehead. 1986. Assessment of the potency of orally administered progestins in women. Fertility and Sterility 46:1062–66. doi:10.1016/S0015-0282(16)49880-8.
   PubMed Web of Science ®Google Scholar
• Kuhl, H. 2011. Pharmacology of progestins. J Reproduktionsmed Endokrinol 8:157–76.
   Google Scholar
• Lobo, R. A., D. F. Archer, R. Kagan, A. M. Kaunitz, G. D. Constantine, J. H. Pickar, S. Graham, B. Bernick, and S. Mirkin. July; 2018. A 17β-Estradiol-Progesterone oral capsule for vasomotor symptoms in postmenopausal women: A randomized controlled trial. Obstetrics and Gynecology 132((1)):161–70. doi: 10.1097/AOG.0000000000002645.
   PubMed Web of Science ®Google Scholar
• Lyytinen, H., E. Pukkala, and O. Ylikorkala. 2009. Breast cancer risk in postmenopausal women using estradiol-progestin therapy. Obstetrics and Gynecology 113:65–73. doi:10.1097/AOG.0b013e31818e8cd6.
   PubMed Web of Science ®Google Scholar
• Manson, J. E., R. T. Chlebowski, M. L. Stefanick, A. K. Aragaki, J. E. Rossouw, R. L. Prentice, G. Anderson, B. V. Howard, et al. 2013. Menopausal hormone therapy and health outcomes during the intervention and extended post stopping phases of the Women’s Health Initiative randomized trials. JAMA 310:1353–68. doi:10.1001/jama.2013.278040.
   PubMed Web of Science ®Google Scholar
• Montplaisir, J., J. Lorrain, R. Denesle, and D. Petit. 2001. Sleep in menopause: Differential effects of two forms of hormone replacement therapy. Menopause 8:10–16. doi:10.1097/00042192-200101000-00004.
   PubMed Web of Science ®Google Scholar
• Mote, P. A., R. L. Balleine, E. M. McGowan, and C. L. Clarke. 2000. Heterogeneity of progesterone receptors A and B expression in human endometrial glands and stroma. Human Reproduction (Oxford, England) 15(Suppl. 3):48–56. doi:10.1093/humrep/15.suppl_3.48.
   PubMed Web of Science ®Google Scholar
• Murkes, D., P. Conner, K. Leifland, E. Tani, A. Beliard, E. Lundström, and G Söderqvist. 2011. Effects of percutaneous estradiol-oral progesterone versus oral conjugated equine estrogensmedroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women. Fertility and Sterility 95:1188–91. doi:10.1016/j.fertnstert.2010.09.062.
   PubMed Web of Science ®Google Scholar
• Nath, A., and R. Sitruk-Ware. 2009. Different cardiovascular effects of progestins according to structure and activity. Climacteric 12 (Suppl1):96–101. doi:10.1080/13697130902905757.
   PubMed Web of Science ®Google Scholar
• Prestwood, K. M., A. M. Kenny, A. Kleppinger, and M. Kulldorff. 2003. Ultralowdose micronized 17beta-estradiol and bone density and bone metabolism in older women: A randomized controlled trial. JAMA 290:1042–48. doi:10.1001/jama.290.8.1042.
   PubMed Web of Science ®Google Scholar
• Prior, J. C. 1990. Progesterone as a bone-trophic hormone. Endocrine Reviews 11:386–98. doi:10.1210/edrv-11-2-386.
   PubMed Web of Science ®Google Scholar
• Prior, J. C., T. G. Elliott, E. Norman, V. Stajic, and C. L. Hitchcock. 2014. Progesterone therapy, endothelial function and cardiovascular risk factors: A 3-month randomized, placebo-controlled trial in healthy early postmenopausal women. PLoS One 9:e84698. doi:10.1371/journal.pone.0084698.
   PubMed Web of Science ®Google Scholar
• Resnick, S. M., M. A. Espeland, S. A. Jaramillo, C. Hirsch, M. L. Stefanick, A. M. Murray, J. Ockene, and C. Davatzikos. 2009. Postmenopausal hormone therapy and regional brain volumes: The WHIMS-MRI Study. Neurology 72:135–42. doi:10.1212/01.wnl.0000339037.76336.cf.
   PubMed Web of Science ®Google Scholar
• Riis, B. J., K. Thomsen, V. Strom, and C. Christiansen. 1987. The effect of percutaneous estradiol and natural progesterone on postmenopausal bone loss. American Journal of Obstetrics and Gynecology 156:61–65. doi:10.1016/0002-9378(87)90203-1.
   PubMed Web of Science ®Google Scholar
• Santen, R. J., D. F. Heitjan, A. Gompel, M. A. Lumsden, J. V. Pinkerton, R. S. Davis, and C. A. Stuenkel. 2020. Underlying breast cancer risk and menopausal hormone therapy. The Journal of Clinical Endocrinology and Metabolism 2020 February 13. pii: dgaa073. 10.1210/clinem/dgaa073. Epub ahead of print
   Web of Science ®Google Scholar
• Schindler, A. E., C. Campagnoli, R. Druckmann, J. Huber, J. R. Pasqualini, K. W. Schweppe, and J. H. H. Thijssen. 2008. Classification and pharmacology of progestins. Maturitas 61:171–80. doi:10.1016/j.maturitas.2008.11.013.
   PubMed Web of Science ®Google Scholar
• Schneider, C., S. S. Jick, and C. R. Meier. 2009. Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations. Climacteric 12:514–24. doi:10.3109/13697130903075352.
   PubMed Web of Science ®Google Scholar
• Schüssler, P., M. Kluge, A. Yassouridis, M. Dresler, K. Held, J. Zihl, and A. Steiger. 2008. Progesterone reduces wakefulness in sleep EEG and has no effect on cognition in healthy postmenopausal women. Psychoneuroendocrinology 33:1124–31. doi:10.1016/j.psyneuen.2008.05.013.
   PubMed Web of Science ®Google Scholar
• Shifren, J. L., and M. L. S. Gass. 2014. The North American menopause society recommendations for clinical care of midlife women. Menopause 21:1038–62. doi:10.1097/GME.0000000000000319.
   PubMed Web of Science ®Google Scholar
• Stanczyk, F. Z., J. P. Hapgood, S. Winer, and J. D. R. Mishell. 2013. Progestins used in postmenopausal hormone therapy: Differences in their pharmacological properties, intracellular actions, and clinical effects. Endococrine Reviews 34:208–13.
   Web of Science ®Google Scholar
• Stuenkel, C. A., S. R. Davis, A. Gompel, M. A. Lumsden, M. H. Murad, J. V. Pinkerton, and R. J. Santen. 2015. Treatment of symptoms of the menopause: An endocrine society clinical practice guideline. The Journal of Clinical Endocrinology and Metabolism 100:3975–4011. doi:10.1210/jc.2015-2236.
   PubMed Web of Science ®Google Scholar
• Stute, P., J. Neulen, and L. Wildt. 2016. The impact of micronized progesterone on the endometrium: A systematic review. Climacteric 19:316–28. doi:10.1080/13697137.2016.1187123.
   PubMed Web of Science ®Google Scholar
• Toit, R. L., K. H. Storbeck, M. Cartwright, A. Cabral, and D. Africander. 2017. Progestins used in endocrine therapy and the implications for the biosynthesis and metabolism of endogenous steroid hormones. Molecular and Cellular Endocrinology 441:31–45. doi:10.1016/j.mce.2016.09.004.
   PubMed Web of Science ®Google Scholar
• Tremollieres, F., M. Brincat, C. T. Erel, M. Gambacciani, I. Lambrinoudaki, M. H. Moen, K. Schenck-Gustafsson, S. Vujovic, S. Rozenberg, M. Rees, et al. 2011. EMAS position statement: Managing menopausal women with a personal or family history of VTE. Maturitas. 69(2):195–98. doi:10.1016/j.maturitas.2011.03.011.
   PubMed Web of Science ®Google Scholar
• Van Gorp, T., and P. Neven. 2002. Endometrial safety of hormone replacement therapy: Review of literature. Maturitas 42:93–104. doi:10.1016/S0378-5122(02)00031-2.
   PubMed Web of Science ®Google Scholar
• Whitehead, M. I., P. T. Townsend, J. Pryse-Davies, T. Ryder, G. Lane, N. C. Siddle, and R. J. King. 1982. Effects of various types and dosages of progestins on the postmenopausal endometrium. The Journal of Reproductive Medicine 27 (8 Suppl.):539–48.
   PubMed Web of Science ®Google Scholar
• Wiegratz, I., and H. Kuhl. 2006. Metabolic and clinical effects of progestins. The European Journal of Contraception and Reproductive Healthcare 11:153–61. doi:10.1080/13625180600772741.
   PubMed Web of Science ®Google Scholar
• The Writing Group for the PEPI trial. 1996. Effects of hormone replacement therapy on endometrial histology in postmenopausal, women. The postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 275: 370–75. doi:10.1001/jama.1996.03530290040035.
   PubMed Web of Science ®Google Scholar